NCT00410358 2020-12-19
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
Novartis
Phase 1 Completed
Clinical Trials
8 trialsNCT00441610 2020-12-19
An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
Novartis
Phase 1 Completed
NCT00493571 2015-05-13
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00087061 2013-07-18
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00420485 2013-04-19
Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00487058 2009-11-19
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00032903 2009-06-03
This is an Early Study to Investigate the Effect of GimatecanĀ® in Adults With Malignant Glioma.
Sigma-Tau Research, Inc.
Phase 1/2 Completed
NCT00033202 2009-06-03
This is an Early Study to Investigate the Effect of GimatecanĀ® in Adults With Solid Tumor
Sigma-Tau Research, Inc.
Phase 1 Completed